GPR40-induced insulin secretion by the novel agonist TAK-875: First clinical findings in patients with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 14, Issue 3, 2012, Pages 271-278

  Araki, T ^a   Hirayama, M ^a   Hiroi, S ^a   Kaku, K ^b  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Free fatty acids; GPR40; Japanese patients; TAK 875; Type 2 diabetes

Indexed keywords

G PROTEIN COUPLED RECEPTOR 40; GLUCOSE; INSULIN; ORAL ANTIDIABETIC AGENT; PLACEBO; TAK 875; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHIL COUNT; FEMALE; FLANK PAIN; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE COUNT;

EID: 84857032603     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01525.x     Document Type: Article

References (27)

1. Cleary PA, Orchard TJ, Genuth S, On Behalf of the DCCT/EDIC Research Group. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes 2006; 55: 3556-3565.
2. Willett LL, Albright ES. Achieving glycemic control in type 2 diabetes: a practical guide for clinicians on oral hypoglycemic. South Med J 2004; 97: 1088-1092.
3. Lebovitz HE. Oral therapies for diabetic hyperglycemia. Endocrinol Metab Clin N Am 2001; 30: 909-933.
4. Burge MR, Sood V, Sobhy TA, Rassam AG, Schade DS. Sulphonylurea-induced hypoglycaemia in type 2 diabetes: a review. Diabetes Obes Metab 1999; 1: 199-206.
5. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
6. Kjems LL, Holst JJ, Volund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on β-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003; 52: 380-386.
7. Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010; 20: 224-235.
8. Stoddart LA, Smith NJ, Milligan G. International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions. Pharmacol Rev 2008; 60: 405-417.
9. Itoh Y, Kawamata Y, Harada M et al. Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40. Nature 2003; 422: 173-176.
10. Nagasumi K, Esaki R, Iwachidow K et al. Overexpression of GPR40 in pancreatic β-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes 2009; 58: 1067-1076.
11. Prentki M, Vischer S, Glennon MC, Regazzi R, Deeney JT, Corkey BE. Malonyl-CoA and long chain acyl-CoA esters as metabolic coupling factors in nutrient-induced insulin secretion. J Biol Chem 1992; 267: 5802-5810.
12. Crespin SR, Greenough WB, Steinberg D. Stimulation of insulin secretion by infusion of free fatty acids. J Clin Invest 1969; 48: 1934-1943.
13. Gravena C, Mathias PC, Ashcroft SJ. Acute effects of fatty acids on insulin secretion from rat and human islets of Langerhans. J Endocrinol 2002; 173: 73-80.
14. Ahrén B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov 2009; 8: 369-385.
15. 2+ channel and link to insulin release. Am J Physiol Endocrinol Metab 2005; 289: E670-677.
16. Shapiro H, Shachar S, Sekler I, Hershfinkel M, Walker MD. Role of GPR40 in fatty acid action on the β cell line INS-1E. Biochem Biophys Res Commun 2005; 335: 97-104.
17. Kebede M, Alquier T, Latour MG, Semache M, Tremblay C, Poitout V. The fatty-acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes 2008; 57: 2432-2437.
18. Steneberg P, Rubins N, Bartoov-Shifman R, Walker MD, Edlund H. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab 2005; 1: 245-258.
19. Gehrmann W, Elsner M, Lenzen S. Role of metabolically generated reactive oxygen species for lipotoxicity in pancreatic β-cells. Diabetes Obes Metab 2010; 12(Suppl 2): 149-158.
20. Rayasam GV, Tulasi VK, Davis JA, Bansal VS. Fatty acid receptors as new therapeutic targets for diabetes. Expert Opin Ther Targets 2007; 11: 661-671.
21. Negoro N, Sasaki S, Mikami S et al. Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist. ACS Med Chem Lett 2010; 1: 290-294.
22. Tan CP, Feng Y, Zhou YP et al. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes 2008; 57: 2211-2219.
23. Naik H, Vakilynejad M, Wu J et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 Agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J Clin Pharmacol 2011 [Epub ahead of print].
24. Flodgren E, Olde B, Meidute-Abaraviciene S, Winzell MS, Ahrén B, Salehi A. GPR40 is expressed in glucagon producing cells and affects glucagon secretion. Biochem Biophys Res Commun 2007; 354: 240-245.
25. Edfalk S, Steneberg P, Edlund H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 2008; 57: 2280-2287.
26. Yang M, Chisholm JW, Soelaiman S, Shryock JC. Sulfonylureas uncouple glucose-dependence for GPR40-mediated enhancement of insulin secretion from INS-1E cells. Mol Cell Endocrinol 2010; 315: 308-313.
27. Seino Y, Nanjo K, Tajima N, et al. The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetol Int 2010; 1: 2-20.